Literature DB >> 1716272

Reduced responsiveness of adenylate cyclase in alveolar macrophages from patients with asthma.

M Bachelet1, D Vincent, N Havet, R Marrash-Chahla, A Pradalier, J Dry, B B Vargaftig.   

Abstract

Alveolar macrophages from patients with asthma accumulated less cyclic adenosine monophosphate when these macrophages were exposed to isobutyl methylxanthine, salbutamol, or prostaglandin E2, compared to cells from control subjects without asthma, and the degree of the hyporesponsiveness was related to the severity of asthma. In addition, a significantly lower adenylate cyclase activity was observed in crude membrane fractions of macrophages from the group with asthma in the presence of salbutamol and prostaglandin E2. The refractoriness observed in patients with asthma is thus not accounted for by a specific beta-adrenergic desensitization at the adenylate cyclase receptor level but should rather be explained by a cyclic adenosine monophosphate-dependent postreceptor mechanism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716272     DOI: 10.1016/0091-6749(91)90093-4

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

1.  The airway effects of stopping regular oral theophylline in patients with asthma.

Authors:  J A Bennett; J Thompson Coon; I D Pavord; P J Wilding; A E Tattersfield
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

2.  Characteristic DNA methylation profiles in peripheral blood monocytes are associated with inflammatory phenotypes of asthma.

Authors:  Lakshitha P Gunawardhana; Peter G Gibson; Jodie L Simpson; Miles C Benton; Rodney A Lea; Katherine J Baines
Journal:  Epigenetics       Date:  2014-08-11       Impact factor: 4.528

3.  BAL Cell Gene Expression in Severe Asthma Reveals Mechanisms of Severe Disease and Influences of Medications.

Authors:  Nathaniel Weathington; Michael E O'Brien; Josiah Radder; Thomas C Whisenant; Eugene R Bleecker; William W Busse; Serpil C Erzurum; Benjamin Gaston; Annette T Hastie; Nizar N Jarjour; Deborah A Meyers; Jadranka Milosevic; Wendy C Moore; John R Tedrow; John B Trudeau; Hesper P Wong; Wei Wu; Naftali Kaminski; Sally E Wenzel; Brian D Modena
Journal:  Am J Respir Crit Care Med       Date:  2019-10-01       Impact factor: 21.405

Review 4.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  The orl rat is more responsive to methacholine challenge than wild type.

Authors:  Elena Rodriguez; Julia S Barthold; Portia A Kreiger; Milena Hirata Armani; Jordan Wang; Katherine A Michelini; Marla R Wolfson; Roberta Boyce; Carol A Barone; Yan Zhu; Scott A Waldman; Thomas H Shaffer
Journal:  Pulm Pharmacol Ther       Date:  2014-09-16       Impact factor: 3.410

6.  Phosphodiesterase 3 inhibition and cough in elderly asthmatics.

Authors:  Yoshihisa Ishiura; Masaki Fujimura; Kouichi Nobata; Miki Abo; Takayoshi Oribe; Shigeharu Myou; Hiroyuki Nakamura
Journal:  Cough       Date:  2005-11-24

Review 7.  Theophylline.

Authors:  Peter J Barnes
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.